Filing Flows

Filing Flows › 8-K events › Arvinas

Arvinas: results of operations

Form 8-K filed Nov 3, 2026 · items 2.02, 7.01

FDA decisionsArvinas Reports Third Quarter 2026 Financial Results and Provides Corporate Update

What the filing says

Arvinas Reports Third Quarter 2026 Financial Results and Provides Corporate Update – Initiated dosing in a Phase 1/2 trial of ARV-6723, an immuno-oncology oral PROTAC designed to degrade HPK1, a negative regulator of immune activation –

Read the filing on SEC EDGAR →

What usually followsAcross 69,115 8-Ks reporting Item 2.02 (results of operations) in our universe, the stock's median move the next session was +0.2% (typical size ±3.6%, up 51% of the time); over the following 21 sessions, +1.2%. Every item ranked →

Arvinas at a glance

Latest quarterQ3 2026
Revenue$500K
Revenue Y/Y-99%
Operating marginn/m
IndustryPharmaceutical Preparations

Arvinas, Q3 2026: revenue $500K (-99% year over year). The chart follows the revenue to costs, profit and cash.

Arvinas: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent fda decisions

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.